Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This review discusses the classification and regulation challenges of anti-ageing cosmetics in Europe and reports no new findings; it calls for increased transparency to help consumers make informed choices.

This study found that people taking Serenoa repens for more than 14 days had a higher likelihood of serious adverse reactions, particularly when also using multiple or interacting supplements, although higher SR doses were linked to lower risk.

Gepant medications for migraines show varied safety profiles in this study, with specific adverse events reported across systems like gastrointestinal and skin disorders, highlighting the need for tailored treatment and monitoring.

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

This paper discusses the methods and challenges of postmarketing surveillance for new antiepileptic drugs, emphasizing the necessity of such data collection to identify adverse effects and assess drug effectiveness beyond initial trials.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.

This retrospective study observed that patients with vascular EDS on long-term angiotensin II receptor blockers or beta-blockers experienced fewer vascular events compared to those without cardiac medication under similar lifestyle and emergency care advice.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.

The document concludes that more research is needed to confirm if COVID-19 vaccines cause a type of hair loss called alopecia areata.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

This chapter reviews adverse effects of anti-anginal and beta-blocker drugs, stating that starting a beta-blocker may temporarily affect driving ability, but it reports no new clinical findings.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

This article discusses developing a standardized operating procedure for PRP administration to align with infection prevention regulatory standards and reports no new clinical results.

This review discusses the various skin changes, pregnancy-specific dermatoses, and medication management related to dermatologic health during pregnancy, aiming to provide clinicians with an evidence-based guide for diagnosis and treatment.

This article reviews the relationship between the skin and the immune system and discusses how skin manifestations can indicate immunodeficiencies but reports no new research findings.

This review discusses the off-label use of drugs like Minoxidil, Aripripazole, and others, providing insights for physicians and pharmacists but reports no new clinical findings.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This study suggests that statins may be linked to various ovary and uterus related adverse events, highlighting the need for monitoring in clinical practice.

This review discusses various nanocarriers for gene and genome editing therapies, highlighting that ionizable lipid nanoparticles show advanced delivery performance, while emerging polymer-based and exosome-inspired carriers are rapidly advancing for targeted applications.

This study confirms known risks of cladribine and reveals potential new safety concerns, emphasizing the need for careful monitoring for early acute toxicity.

This study found that most adverse events reported for HPV vaccines in the VAERS system were non-serious and already known, although less common events suggest the need for further examination.